Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Month: June 2007
-
By Kevin E. Noonan — Craig Venter’s colleagues at the J. Craig Venter Institute show no signs that recent vocal criticism of their work in synthetic biology has made a dent in their determination to "create life" (see "Patenting Life (Really)"). They report in this week’s Science Express (an online journal of pre-publication…
-
By Donald Zuhn — On Thursday, the U.S. Patent and Trademark Office announced that it would extend the Patent Prosecution Highway (PPH) pilot program for an additional six months. The PPH pilot program, which the office began almost a year ago on July 3, 2006, allows an applicant having an application whose claims…
-
By Kevin E. Noonan — Peter Duesberg is at it again. Pioneering virologist and molecular biologist, purported genius, and member of the U.S. National Academy of Science, Professor Duesberg is predominantly and (in)famously a scientific contrarian, quick, even eager to tell other scientists that they are wrong – not just wrong about a…
-
By Jason Derry — Novogen Ltd. and Chattem, Inc. have reached a settlement, ending the legal action regarding isoflavone-containing health supplements. Novogen filed suit against Chattem, alleging that certain Chattem menopause products infringed two of Novogen’s U.S. patents – in particular, U.S. Patent Nos. 6,562,380 and 6,987,098. Novogen has previously enforced its patents…
-
Complete Ownership Is Required to Sue for Infringement By Baltazar Gomez — On June 18, 2007, the U.S. Supreme Court denied a petition from Israel Bio-Engineering Project (IBEP) for a writ of certiorari, and let stand an Federal Circuit ruling that IBEP cannot sue for infringement because it failed to show full patent…
-
By Kevin E. Noonan — On a website that has been active only since late last year, scientist and web guru Moshe Pritsker is collecting videos demonstrating an ever-growing collection of scientific experiments as a way of providing the hardest part of making a new protocol work in practice: actually seeing it work. …
-
By Donald Zuhn — As we reported yesterday, Roche announced on Monday that it had made an offer to acquire Ventana Medical Systems, Inc. for $75 per share, or approximately $3 billion. Today, Roche announced that it has commenced a cash tender offer for all outstanding shares of Ventana common stock. The terms…
-
By Kevin E. Noonan — The Wisconsin Alumni Research Foundation (WARF) has now responded to the U.S. Patent and Trademark Office’s rejections of its stem cell patents in reexamination. These patents, U.S. Patent Nos. 5,843,780 (claiming primate embryonic stem (pES) cells); 6,200,806 (claiming human embryonic stem cell (hES) cells); and 7,029,913 (hES) (collectively,…
-
By Donald Zuhn — On Monday, Roche announced that it had made an offer to acquire Ventana Medical Systems, Inc. for $75 per share, or approximately $3 billion. According to a New York Times report, the Swiss-based biotech’s offer constitutes a 45% premium over Ventana’s Monday closing stock price of $51.74. According to…
-
By Kevin E. Noonan — After a thorough review by a peer-review panel of the scientific data presented in a report published in its pages five years ago, the journal Nature announced on June 14, 2007 that, although representation of the data in one figure was flawed, the underlying conclusions were scientifically valid. …
Patent Docs 